DB:8C5

Stock Analysis Report

Executive Summary

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide.


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Coherus BioSciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 8C5's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

3.0%

8C5

-4.3%

DE Biotechs

-4.7%

DE Market


1 Year Return

54.1%

8C5

5.5%

DE Biotechs

8.3%

DE Market

Return vs Industry: 8C5 exceeded the German Biotechs industry which returned 5.5% over the past year.

Return vs Market: 8C5 exceeded the German Market which returned 8.3% over the past year.


Shareholder returns

8C5IndustryMarket
7 Day3.0%-4.3%-4.7%
30 Day19.6%-6.7%-4.0%
90 Day21.5%0.4%-1.4%
1 Year54.1%54.1%5.8%5.5%11.7%8.3%
3 Year-2.5%-2.5%40.9%39.4%11.4%1.6%
5 Year-26.3%-26.3%10.9%8.6%15.1%-0.7%

Price Volatility Vs. Market

How volatile is Coherus BioSciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Coherus BioSciences undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 8C5 (€20.28) is trading below our estimate of fair value (€57.24)

Significantly Below Fair Value: 8C5 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 8C5 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: 8C5 is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 8C5's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 8C5 is overvalued based on its PB Ratio (27.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Coherus BioSciences forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

25.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8C5 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.4%).

Earnings vs Market: 8C5 is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: 8C5's is expected to become profitable in the next 3 years.

Revenue vs Market: 8C5's revenue (15.7% per year) is forecast to grow faster than the German market (5.1% per year).

High Growth Revenue: 8C5's revenue (15.7% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: 8C5's Return on Equity is forecast to be high in 3 years time (39.9%)


Next Steps

Past Performance

How has Coherus BioSciences performed over the past 5 years?

-2.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 8C5 is currently unprofitable.

Growing Profit Margin: 8C5 is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: 8C5 is unprofitable, and losses have increased over the past 5 years at a rate of -2.4% per year.

Accelerating Growth: Unable to compare 8C5's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 8C5 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 8C5 has a negative Return on Equity (-21.4%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Coherus BioSciences's financial position?


Financial Position Analysis

Short Term Liabilities: 8C5's short term assets ($276.4M) exceed its short term liabilities ($82.7M).

Long Term Liabilities: 8C5's short term assets ($276.4M) exceed its long term liabilities ($188.7M).


Debt to Equity History and Analysis

Debt Level: 8C5's debt to equity ratio (317.3%) is considered high.

Reducing Debt: Insufficient data to determine if 8C5's debt to equity ratio has reduced over the past 5 years.


Balance Sheet

Inventory Level: 8C5 has a low level of unsold assets or inventory.

Debt Coverage by Assets: 8C5's debt is covered by short term assets (assets are 1.6x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 8C5 has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if 8C5 has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Coherus BioSciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.7%industryaverage1.0%forecastin3Years0%

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate 8C5's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 8C5's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 8C5's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 8C5's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 8C5's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.9yrs

Average management tenure


CEO

Denny Lanfear (64yo)

9.4yrs

Tenure

US$3,919,780

Compensation

Mr. Dennis M. Lanfear, also known as Denny, has been the Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Cap ...


CEO Compensation Analysis

Compensation vs Market: Denny's total compensation ($USD3.92M) is above average for companies of similar size in the German market ($USD1.62M).

Compensation vs Earnings: Denny's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Dennis Lanfear
Chairman9.4yrsUS$3.92m0.87% $12.7m
Jean-Frédéric Viret
Chief Financial Officer5.4yrsUS$1.48m0.022% $323.6k
Vincent Anicetti
Chief Operating Officer1.8yrsUS$1.82m0.031% $451.4k
Vladimir Vexler
Chief Scientific Officer1.3yrsUS$1.36m0.036% $517.6k
V. Lawlis
Science Director7.3yrsUS$212.28kno data
Barbara Finck
Chief Clinical Advisor0yrsUS$1.55m0.071% $1.0m
Peter Watler
Chief Technical Officer5.7yrsUS$971.52kno data
David Arrington
Vice President of Investor Relations & Corporate Affairs0yrsno datano data
Thomas Fitzpatrick
Chief Legal Officer0.9yrsno datano data
Erik Wiberg
Executive Vice President of Corporate Development2.9yrsno datano data

2.9yrs

Average Tenure

64yo

Average Age

Experienced Management: 8C5's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dennis Lanfear
Chairman9.4yrsUS$3.92m0.87% $12.7m
V. Lawlis
Science Director7.3yrsUS$212.28kno data
Barbara Finck
Chief Clinical Advisor0yrsUS$1.55m0.071% $1.0m
James Healy
Independent Director6yrsUS$199.78k0.10% $1.5m
Mats Wahlström
Lead Independent Director0yrsUS$229.78k0.45% $6.6m
Mary Szela
Independent Director5.6yrsUS$187.28kno data
Ali Satvat
Independent Director5.8yrsUS$184.78kno data
James Daly
Executive Chairman of Commercial Advisory Committee4yrsno datano data
Alan Herman
Chairman Emeritus & Member of Advisory Board1.3yrsUS$1.19mno data
Christos Richards
Director8.9yrsUS$174.78k0.091% $1.3m

5.9yrs

Average Tenure

63yo

Average Age

Experienced Board: 8C5's board of directors are considered experienced (5.9 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 17.2%.


Top Shareholders

Company Information

Coherus BioSciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Coherus BioSciences, Inc.
  • Ticker: 8C5
  • Exchange: DB
  • Founded: 2010
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$1.580b
  • Listing Market Cap: US$1.456b
  • Shares outstanding: 70.13m
  • Website: https://www.coherus.com

Number of Employees


Location

  • Coherus BioSciences, Inc.
  • 333 Twin Dolphin Drive
  • Suite 600
  • Redwood City
  • California
  • 94065
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
CHRSNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 2014
8C5DB (Deutsche Boerse AG)YesCommon StockDEEURNov 2014

Biography

Coherus BioSciences, Inc., a commercial-stage biotherapeutics company, focuses on the biosimilar market worldwide. It markets UDENYCA, a long-acting granulocyte-colony stimulating factor, which stimulates production of granulocytes in order to promote the body’s ability to fight infections. The company sells UDENYCA in the United States. Its clinical-stage product candidates include immunology, anti-tumor necrosis factor biosimilar candidates, CHS-1420 for adalimumab and CHS-0214 for etanercept, which has completed Phase III clinical programs; ophthalmology biosimilar candidates, CHS-3351 for ranibizumab and CHS-2020 for aflibercept that is in preclinical development; and CHS-131, small molecule therapeutic candidate and other metabolic conditions. Coherus BioSciences, Inc. has collaboration and license agreements with Daiichi Sankyo Company, Limited; Baxalta Incorporated; Baxalta US Inc.; Baxalta GmbH; and Selexis SA. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was founded in 2010 and is headquartered in Redwood City, California. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/24 23:06
End of Day Share Price2020/02/24 00:00
Earnings2019/09/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.